Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AZN
stocks logo

AZN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
15.48B
+3.95%
1.085
+3.85%
14.39B
+5.93%
1.260
+1.2%
14.88B
+2.93%
1.100
+1.38%
Estimates Revision
The market is revising Upward the revenue expectations for AstraZeneca PLC (AZN) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by 10.09%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+101.54%
In Past 3 Month
Stock Price
Go Up
up Image
+10.09%
In Past 3 Month
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 94.00 USD with a low forecast of 85.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 94.00 USD with a low forecast of 85.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 90.030
sliders
Low
85.00
Averages
94.00
High
101.00
Current: 90.030
sliders
Low
85.00
Averages
94.00
High
101.00
Guggenheim
Buy
maintain
2025-12-03
New
Reason
Guggenheim
Price Target
2025-12-03
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on AstraZeneca to 15,500 GBp from 14,200 GBp and keeps a Buy rating on the shares, citing strong year-to-date performance, increased sales for Enhertu outside of the U.S. and Ultomiris, and SG&A leverage. The firm believes AstraZeneca, its preferred name among EU drugmakers for 2026, warrants a premium multiple to the group as "the most reliable growth story in EU Pharma" with potential for further catalyst-driven upside, the analyst tells investors.
Morgan Stanley
NULL -> Overweight
upgrade
$93 -> $103
2025-12-03
New
Reason
Morgan Stanley
Price Target
$93 -> $103
2025-12-03
New
upgrade
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on AstraZeneca to $103 from $93 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Jefferies
Michael Leuchten
Buy
initiated
£15,000
2025-10-27
Reason
Jefferies
Michael Leuchten
Price Target
£15,000
2025-10-27
initiated
Buy
Reason
Jefferies analyst Michael Leuchten assumed coverage of AstraZeneca with a Buy rating and 15,000 GBp price target. Given what the firm sees as likely outperformance of in-market oncology franchises and the biopharma pipeline, the firm argues that the company's 2030 $80B sales target is "in sight and is lower risk than perceived."
Deutsche Bank
Hold
to
Sell
downgrade
2025-10-16
Reason
Deutsche Bank
Price Target
2025-10-16
downgrade
Hold
to
Sell
Reason
Deutsche Bank downgraded AstraZeneca to Sell from Hold with a price target of 10,500 GBp, down from 11,000 GBp. The shares are trading at the top of their recent range while AstraZeneca is "much closer to material patent pressures," the analyst tells investors in a research note. Deutsche has reduced confidence in AstraZeneca's pipeline outlook following an analysis into the breast cancer space.
BTIG
Buy
upgrade
$87 -> $104
2025-09-24
Reason
BTIG
Price Target
$87 -> $104
2025-09-24
upgrade
Buy
Reason
BTIG raised the firm's price target on Monopar Therapeutics (MNPR) to $104 from $87 and keeps a Buy rating on the shares. The company announced a published letter to the editor by leading Wilson's disease key opinion leaders in the Journal of Hepatology detailing an updated copper balance analysis from the Phase 2 copper balance study conducted by AstraZeneca (AZN), the analyst tells investors in a research note. The firm says the authors' conclusions provide an external validation of Monopar's view that AstraZeneca's copper balance calculation was flawed, with patient by patient data showing consistent negative trends in copper balance. BTIG believes the update "provides a solid data point" for Monopar to discuss with the FDA as it prepares for a new drug application in early 2026. The firm upped its probability of success for ALXN1840 to 50% from 40%.
Leerink
Outperform
maintain
$10 -> $13
2025-08-07
Reason
Leerink
Price Target
$10 -> $13
2025-08-07
maintain
Outperform
Reason
Leerink raised the firm's price target on Compugen (CGEN) to $13 from $10 and keeps an Outperform rating on the shares. Compugen's partner AstraZeneca's (AZN) continued expansion of rilvegostomig meaningfully derisks the royalty stream to Compugen, minimizing capital risk and setting a baseline valuation for Compugen, in the firm's view. Earlier-stage assets including the company's wholly owned COM701 and COM503 provide additional upside, Leerink adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for AstraZeneca PLC (AZN.O) is 0.00, compared to its 5-year average forward P/E of 16.95. For a more detailed relative valuation and DCF analysis to assess AstraZeneca PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
16.95
Current PE
0.00
Overvalued PE
21.16
Undervalued PE
12.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
13.91
Current EV/EBITDA
14.34
Overvalued EV/EBITDA
15.17
Undervalued EV/EBITDA
12.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
4.22
Current PS
4.66
Overvalued PS
4.60
Undervalued PS
3.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 166.61% over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AZN News & Events

Events Timeline

(ET)
2025-12-04
16:10:00
Salesforce Partners with AstraZeneca to Enhance Customer Engagement
select
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Benzinga
PinnedAstraZeneca's Hypertension Medication Progresses, FDA Decision Anticipated in 2026

  • FDA Acceptance: The U.S. FDA has accepted AstraZeneca's New Drug Application for baxdrostat, aimed at treating adult patients with hard-to-control hypertension as an add-on to existing antihypertensive medications.

  • Hypertension Statistics: Approximately 1.4 billion people globally suffer from hypertension, with about 50% of U.S. patients on multiple treatments failing to achieve controlled blood pressure.

  • Clinical Trial Results: The NDA is supported by data from the BaxHTN Phase 3 trial, which demonstrated significant reductions in systolic blood pressure for baxdrostat compared to placebo, with consistent results across different patient subgroups.

  • Future Developments: The Prescription Drug User Fee Act date is expected in Q2 2026, and baxdrostat is also being studied in various clinical trials for hypertension, primary aldosteronism, and other conditions.

[object Object]
Preview
9.0
12-02NASDAQ.COM
PinnedFDA Grants Priority Review for AstraZeneca's Hypertension Medication Baxdrostat

  • FDA Priority Review: AstraZeneca's new drug application for baxdrostat, an experimental hypertension drug, has been granted Priority Review by the FDA, with a PDUFA date set for the second quarter of 2026.

  • Targeting Resistant Hypertension: Baxdrostat aims to inhibit aldosterone synthase, addressing resistant hypertension, a condition affecting about half of U.S. patients with uncontrolled blood pressure despite multiple medications.

  • Clinical Trial Results: The Phase III BaxHTN trial demonstrated significant reductions in systolic blood pressure, with the 2mg dose achieving a placebo-adjusted reduction of 9.8 mmHg at 12 weeks.

  • Commitment to Innovation: AstraZeneca emphasizes its commitment to advancing baxdrostat as a potential first-in-class treatment for difficult-to-control hypertension, highlighting its novel mechanism of action and well-tolerated profile.

[object Object]
Preview
3.0
07:13 AMYahoo Finance
Is There More Room for Growth After AstraZeneca's Impressive 30% Surge in 2025?

  • Current Stock Performance: AstraZeneca's stock has seen a slight decline of 3.6% recently, following a strong 30.0% return over the past year and an 87.0% increase over five years, supported by advancements in its oncology and immunology pipelines.

  • Valuation Insights: A Discounted Cash Flow analysis indicates that AstraZeneca is undervalued by approximately 43.0%, with an estimated intrinsic value of $237.27 per share compared to its current price.

  • Price to Earnings Ratio: AstraZeneca's current PE ratio of 29.8x is above industry averages, suggesting investors are paying a premium for its earnings, yet it appears modestly undervalued compared to a calculated Fair Ratio of 31.2x.

  • Narrative Approach to Valuation: The article introduces a Narrative framework for investors to connect their expectations for AstraZeneca's future performance with financial forecasts, allowing for a personalized assessment of the stock's fair value.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AstraZeneca PLC (AZN) stock price today?

The current price of AZN is 90.03 USD — it has decreased -0.9 % in the last trading day.

arrow icon

What is AstraZeneca PLC (AZN)'s business?

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.

arrow icon

What is the price predicton of AZN Stock?

Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 94.00 USD with a low forecast of 85.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AstraZeneca PLC (AZN)'s revenue for the last quarter?

AstraZeneca PLC revenue for the last quarter amounts to 15.19B USD, increased 11.99 % YoY.

arrow icon

What is AstraZeneca PLC (AZN)'s earnings per share (EPS) for the last quarter?

AstraZeneca PLC. EPS for the last quarter amounts to 1.62 USD, increased 78.02 % YoY.

arrow icon

What changes have occurred in the market's expectations for AstraZeneca PLC (AZN)'s fundamentals?

The market is revising Upward the revenue expectations for AstraZeneca PLC (AZN) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by 10.09%.
arrow icon

How many employees does AstraZeneca PLC (AZN). have?

AstraZeneca PLC (AZN) has 94300 emplpoyees as of December 05 2025.

arrow icon

What is AstraZeneca PLC (AZN) market cap?

Today AZN has the market capitalization of 279.14B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free